Menu Search
Equities

Hemostemix Inc

2VF0:FRA

Hemostemix Inc

Actions
  • Price (EUR)0.0345
  • Today's Change-0.003 / -6.76%
  • Shares traded1.50k
  • 1 Year change-28.87%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 14:29 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-1.94m
  • Incorporated2014
  • Employees--
  • Location
    Hemostemix Inc707 7th Ave. SW, Suite 1150CALGARY T2P 3H6CanadaCAN
  • Phone+1 (905) 580-4170
  • Fax+1 (403) 818-7672
  • Websitehttps://hemostemix.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.